Advertisement

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Related Videos

William M. Sikov, MD

William M. Sikov, MD, on the CALGB 40603 Trial

William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."

Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial

Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Hope S. Rugo, MD

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy,” presented by Rowan T. Chlebowski, MD.

Hope S. Rugo, MD

Hope S. Rugo, MD, on the Phase II FIRST Study

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.

Lisa A. Carey, MD

Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer

Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Advertisement

Advertisement

May

25

Today In Oncology

Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status

FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer

Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma

Advertisement

© 2026 HSP News Service, L.L.C.